Praluent Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
This slideshow shows drug information for Evkeeza. Click here for the complete Evkeeza monograph.
Event rates for time to first fatal or nonfatal stroke significantly reduced for IPE versus placebo
For participants reporting muscle symptoms when taking statins, no overall effect seen for atorvastatin 20mg vs placebo
Among solo providers, there was little difference in care management and outcomes between physicians, nonphysicians
56.4 percent aged 75 years and older using statin for secondary cardiovascular event prevention; 45.3 percent taking aspirin for primary prevention
An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.
The approval was based on data from the double-blind, placebo-controlled phase 3 ELIPSE HoFH trial.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.